SciVision Biotech Inc. (TPE:1786)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
46.30
+0.40 (0.87%)
Sep 8, 2026, 1:30 PM CST

SciVision Biotech Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
178.11162.34242.25177.9141.72101.72
Depreciation & Amortization
87.5980.3665.1463.0562.0252.98
Other Amortization
0.080.070.080.080.040.04
Loss (Gain) From Sale of Assets
00.01-0.19-0.54-30.55-0.13
Loss (Gain) From Sale of Investments
-1.252.13-6.45-2.91.980.13
Other Operating Activities
18.87-4.0725.997.4318.12-2.23
Change in Accounts Receivable
-83.65-75.5-73.55-4.85-7.77-10.47
Change in Inventory
-21.31-13.7414.458.62-13-37.03
Change in Accounts Payable
11.863.136.52-3.216.77-11.33
Change in Unearned Revenue
-4.01-1.13-4.346.32-1.01-5.6
Change in Other Net Operating Assets
-67.5-29.6-0.0420.113.6810.41
Operating Cash Flow
118.78123.99269.87272.01181.9998.51
Operating Cash Flow Growth
-55.08%-54.06%-0.79%49.47%84.75%-22.11%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-66.01-101.53-34.76-14.73-14.96-25.78
Sale of Property, Plant & Equipment
1.11-0.191.2656.4821.13
Sale (Purchase) of Intangibles
-0.22-0.23-0.12-0.11--
Investment in Securities
-105.82-39.79134-201.79-48.49-20.89
Other Investing Activities
1.57-1.19-1.792.0152.79-51.47
Investing Cash Flow
-169.36-142.7497.52-213.3745.81-77.01

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-2---10
Long-Term Debt Issued
-400--7001,200
Total Debt Issued
400.5402--7001,210
Short-Term Debt Repaid
--1.49----10
Long-Term Debt Repaid
--8.1-3.35-1.23-905.89-901.39
Lease Payments
-12.84-8.1-3.35-1.23-1.37-1.39
Total Debt Repaid
-14.84-9.6-3.35-1.23-905.89-911.39
Net Debt Issued (Repaid)
385.66392.4-3.35-1.23-205.89298.61
Repurchase of Common Stock
-107.06-----
Common Dividends Paid
-142.84-233.87-169.33-133.3-93.83-58.56
Other Financing Activities
--0.16-0.01-
Financing Cash Flow
135.77158.53-172.52-134.53-299.71240.06

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
0.2200.05-0.030.01-0.01
Net Cash Flow
85.41139.79194.92-75.92-71.9261.55

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
52.7722.46235.11257.28167.0372.73
Free Cash Flow Growth
-72.25%-90.45%-8.62%54.04%129.64%21.97%
Free Cash Flow Margin
5.93%2.53%26.62%36.08%29.97%14.39%
Free Cash Flow Per Share
0.690.293.163.372.241.02
Levered Free Cash Flow
-163.57-82.15134.06189.2199.159.36
Unlevered Free Cash Flow
-156.2-77.19137.61194.35103.1814.4
Free Cash Flow After Leases
39.9414.36231.76256.05165.6671.35

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
0.220.030.990.422.991.12
Cash Income Tax Paid
25.2338.0328.630.9711.5123.53
Change in Working Capital
-164.62-116.84-56.9626.99-11.33-54.01